Nasdaq Stockholm AB has today decided to admit the shares of Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) for trading on Nasdaq Stockholm with first day of trading tomorrow, Wednesday 13 March 2019. The shares will be traded under the ticker ACE and ISIN SE0010573113. The offering in Ascelia Pharma AB in connection with the listing on Nasdaq Stockholm was, as previously communicated, significantly oversubscribed. The offering provided Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the offering.
The offering in Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the Offering.
Arcomas kvartalsrapport för fjärde kvartalet 2018 – bokslutskommuniké – finns att läsa här
Sunstone Capital today announce that the two investment arms of Sunstone – Life Science Ventures and Technology Ventures – in the future will operate under the names Sunstone Life Science Ventures ( https://sunstone.eu ) and Heartcore Capital, respectively.
Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) has decided to issue new shares to the general public in Sweden and Denmark as well as institutional investors in Sweden and abroad (the “Offering”). The Company’s Board of Directors also intend to apply for admission to trading of the Company’s shares on Nasdaq Stockholm after Nasdaq Stockholm AB’s announcement that the Company complies with Nasdaq Stockholm’s listing requirements, provided that certain conditions and customary requirements, including the dispersion requirement for the Company’s shares, are fulfilled. The prospectus for the Offering, including the price and other terms of the Offering, is published today. The first day of trading is expected to be March 13, 2019.